Skip to main content

Table 2 Contribution of bone marrow aspiration to diagnosis and treatment

From: Contribution to diagnosis and treatment of bone marrow aspirate results in critically ill patients undergoing bone marrow aspiration: a retrospective study of 193 consecutive patients

Patient Indication Diagnostic contribution, N = 37 Therapeutic contribution, N = 14
1 b Hemophagocytic syndrome No
2 (a) b Maturation arrest of granulocyte precursors No
3 (a) c Acute transformation of CMML DFLST
4 d Maturation arrest of granulocyte precursors No
5 (a) c Maturation arrest of granulocyte precursors No
6 c No (normal marrow) Addition of erythropoietin
7 c Marginal zone lymphoma No
8 (a) c No (normal marrow) Addition of dasatinib
9 (a) e Maturation arrest of granulocyte precursors Discontinuation of TMP/SMX
10 e Hemophagocytic syndrome No
11 c Lymphocytic lymphoma No
12 e No (presence of phagocytic histiocytes) Addition of etoposide
13 e Myelodysplastic syndrome No
14 b Hemophagocytic syndrome No
15 c Diffuse large B cell lymphoma Addition of COP (g)
16 c Marginal zone lymphoma No
17 d Maturation arrest of granulocyte precursors No
18 (a) c Acute monocytic leukemia DFLST
19 c Acute myeloid leukemia DFLST
20 e Hemophagocytic syndrome No
21 e Hemophagocytic syndrome No
22 c Myelodysplastic syndrome No
23 (a) c Relapsed multiple myeloma No
24 e Hemophagocytic syndrome No
25 d Maturation arrest of granulocyte precursors Discontinuation of tacrolimus
26 e Hemophagocytic syndrome No
27 (a) c Hemophagocytic syndrome No
28 c Multiple myeloma No
29 e Myelodysplastic syndrome No
30 e Myelodysplastic syndrome No
31 b Hemophagocytic syndrome No
32 f Diffuse large B cell lymphoma Addition of COP (g)
33 (a) c Myelodysplastic syndrome No
34 e Hemophagocytic syndrome Addition of etoposide
35 (a) c Hemophagocytic syndrome No
36 e Hemophagocytic syndrome No
37 d Maturation arrest of granulocyte precursors Addition of lenogastrim
38 d Maturation arrest of granulocyte precursors Discontinuation of amoxicillin
39 d Maturation arrest of granulocyte precursors Addition of lenogastrim
40 (a) c Maturation arrest of granulocyte precursors No
  1. In patients 6, 8, and 12, BMA did not contribute to diagnosis but contributed to treatment
  2. a, hematological malignancy or cancer already known upon ICU admission; b, suspicion of hemophagocytic lymphohistiocytosis; c, suspicion of hematological malignancy; d, agranulocytosis; e, thrombocytopenia; f, suspected cancer that has spread to the bone marrow; g, ultimately followed by DFLST; CMML, chronic myelomonocytic leukemia; COP, cyclophosphamide, vincristine, prednisone; DFLST, decision to forego life-sustaining treatment; TMP/SMX, trimethoprim/sulfamethoxazole